XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
2019 bonus payout in RSUs
Common Stock
2019 bonus payout in RSUs
Additional Paid-In Capital
2019 bonus payout in RSUs
Common Stock
At The Market Offering.
Common Stock
Additional Paid-In Capital
At The Market Offering.
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Cumulative translation adjustment
Accumulated Other Comprehensive Loss
Accumulated Deficit
Cumulative translation adjustment
At The Market Offering.
Total
Beginning Balances at Dec. 31, 2019         $ 7   $ 1,000,763   $ (558) $ (894,998)     $ 105,214
Beginning Balances (in shares) at Dec. 31, 2019         70,366,661                
Net loss                   132,244     132,244
Issuance of common stock upon exercise of stock options             17,061           17,061
Issuance of common stock upon exercise of stock options (in shares)         1,704,764                
Issuance of common stock upon vesting of RSUs   $ 2,378 $ 2,378                    
Issuance of common stock upon vesting of RSUs (in shares) 134,099       89,668                
Stock-based compensation expense             39,038           39,038
Issuance of common stock under the ESPP             3,801           3,801
Issuance of common stock under the ESPP (in shares)         267,772                
Taxes paid related to net share settlement of RSUs             (880)           (880)
Taxes paid related to net share settlement of RSUs (in shares)         (49,616)                
Purchase of capped call options related to convertible notes due 2026             18,170           18,170
Cumulative translation adjustment               $ 288     $ 288   288
Ending Balances at Dec. 31, 2020         $ 7   1,043,991   (270) (762,754)     280,974
Ending Balances (in shares) at Dec. 31, 2020         72,513,348                
Net loss                   (287,100)     (287,100)
Issuance of common stock upon exercise of stock options             10,410           10,410
Issuance of common stock upon exercise of stock options (in shares)         1,316,361                
Issuance of common stock upon vesting of RSUs (in shares)         465,930                
Stock-based compensation expense             51,290           51,290
Issuance of common stock to Shanghai Junshi Biosciences Ltd. ("Junshi Biosciences"), net of issuance costs             40,903           40,903
Issuance of common stock to Shanghai Junshi Biosciences Ltd. ("Junshi Biosciences"), net of issuance costs (in shares)         2,491,988                
Issuance of common stock under the ESPP             3,002           3,002
Issuance of common stock under the ESPP (in shares)         238,934                
Stock Issued During Period Value New Issues             40,903           40,903
Taxes paid related to net share settlement of RSUs             (1,753)           (1,753)
Taxes paid related to net share settlement of RSUs (in shares)         (96,465)                
Ending Balances at Dec. 31, 2021         $ 7   1,147,843   (270) (1,049,854)     $ 97,726
Ending Balances (in shares) at Dec. 31, 2021         76,930,096               76,930,096
Net loss                   (291,754)     $ (291,754)
Issuance of common stock upon exercise of stock options             691           691
Issuance of common stock upon exercise of stock options (in shares)         141,897                
Issuance of common stock upon vesting of RSUs (in shares)         806,854                
Stock-based compensation expense             51,188           51,188
Issuance of common stock under ATM Offering, net of issuance costs       $ 1   $ 6,133           $ 6,134  
Issuance of common stock to Shanghai Junshi Biosciences Ltd. ("Junshi Biosciences"), net of issuance costs (in shares)       916,884               916,884  
Issuance of common stock under the ESPP             2,320           2,320
Issuance of common stock under the ESPP (in shares)         347,883                
Taxes paid related to net share settlement of RSUs             (3,744)           (3,744)
Taxes paid related to net share settlement of RSUs (in shares)         (292,098)                
Other comprehensive gain (loss), net of tax                 21       21
Cumulative translation adjustment                         (1)
Ending Balances at Dec. 31, 2022         $ 8   $ 1,204,431   $ (249) $ (1,341,608)     $ (137,418)
Ending Balances (in shares) at Dec. 31, 2022         78,851,516               78,851,516